Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.85 +0.08 (+0.33%)
Streaming Delayed Price Updated: 10:10 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
3 Reasons Relying on Social Security Alone Could be a Risk. And 3 Stocks to Invest in Today.
Social Security is likely to deliver less income than you expect. But you can make up the difference and more via dividend-paying stocks. 
Via The Motley Fool
Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. 
Via Benzinga
GSK Stock Crumbles As Vaccine Sales Plummet And Miss Expectations
The company said revenue from RSV vaccine tumbled 72%. 
Via Investor's Business Daily
Pfizer Earnings Top Q3 Views; Pharma Giant Guides Higher
The drug giant comfortably beat estimates and raised full-year guidance. 
Via Investor's Business Daily
Stocks Going Ex Dividend In November 2024
The following is a short list of some of the many stocks going ex-dividend during the next month. 
Via Talk Markets
AWKO Files Lawsuit on Behalf of Sickle Cell Patient Against Pfizer’s Subsidiary
San Francisco, California - Trebor Hardiman, a sickle cell patient from California, has filed a lawsuit against Pfizer’s wholly owned subsidiary Global Blood 
Via Law Firm Newswire
Topics Lawsuit
Exposures Financial Legal
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
Pfizer's dividends should keep flowing and growing. 
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
Nasdaq Hits Record High Ahead Of Big Tech Earnings: Fear Index Remains In 'Greed' Zone
Via Benzinga
Why Pfizer Stock Tumbled on Tuesday
The specter of an activist investor looms over the company. 
Via The Motley Fool
Pfizer (PFE) Q3 2024 Earnings Call Transcript
PFE earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biotech Momentum Trades For The Q4 Rally
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
Tech Stocks Rise Ahead Of Key Earnings, Gold Smashes Records, Bitcoin Nears All-Time Highs: What's Driving Markets Tuesday?
Wall Street took a breather on Tuesday, with most major indices treading water, while tech stocks saw gains as investors braced for earnings reports from mega-cap companies. 
Via Benzinga
Nasdaq Surges Over 100 Points; Pfizer Earnings Top Views
Via Benzinga
Pfizer Inc.’s Strong Q3 Performance: Beats Expectations With $1.06 EPS
Pfizer Inc. reported stellar third-quarter financial results, with revenues surging to $17.7 billion. 
Via Talk Markets
Pfizer Q3 Earnings: Revenue And Profit Beat On Heightened Demand For Paxlovid, Expects $10 Billion In 2024 Revenue From COVID Products
Pfizer reports Q3 EPS of $1.06, surpassing $0.62 consensus, with revenue up 31% to $17.7 billion. Growth driven by Paxlovid, Comirnaty, and Seagen contributions. 
Via Benzinga
Exposures COVID-19
US Stocks Likely To Open Weaker As Investors Eye Alphabet, AMD And Pfizer Earnings: Expert Says Won't Be 'Surprised' If Earnings Exceed Wall Street Expectations
U.S. stocks could see a weak opening on Tuesday after the averages registered a mixed last week. 
Via Benzinga
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer, Alphabet And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
What Lies In Store For Healthcare ETFs In Q3 Earnings?
The healthcare sector has performed well in recent months, driven by the booming weight-loss drug treatment segment. As such, various healthcare ETFs have benefited. 
Via Talk Markets
Topics ETFs
These 7 Blunt Words Just Opened a Can of Worms For Pfizer's Stock
The company's problems are no longer deniable. 
Via The Motley Fool
3 Magnificent S&P 500 Dividend Stocks Down 43%, 20%, and 53% to Buy and Hold Forever
The market is overlooking the bigger picture for these three names. That means opportunity for you. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Spooky Signs That You're About to Lose Your Money on a Healthcare Stock Investment
Knowing these will help you avoid making suboptimal investing decisions. 
Via The Motley Fool
Pfizer, Live Nation Entertainment And More On CNBC's 'Final Trades'
Pfizer shares fell 0.8% to close at $28.64 during Thursday's session. Live Nation Entertainment shares gained 1.5% to close at $116.45. 
Via Benzinga
Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.
These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors. 
Via The Motley Fool
3 Sweet Dividend Stocks to Treat Your Portfolio With This Halloween
There are more reasons to buy these stocks besides their high payouts. 
Via The Motley Fool
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for millions at risk of serious disease. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.